Lonza released its 9m trading statement which does not include any hard numbers (as usual) and only stresses the continued positive momentum in both Speciality Ingredients and Pharma&Biotech. As a reminder, top-line growth in H1 was +5.8% (and +6.5% at CER). The group's outlook remains unchanged (sales growth in reported currency and core EBIT growth above +5% at CER with capex below CHF300m and a reduction in net debt).
29 Oct 2015
Q3 trading statement: management's confidence reiterated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 trading statement: management's confidence reiterated
Lonza Group AG (0QNO:LON) | 0 0 0.0% | Mkt Cap: 22,735m
- Published:
29 Oct 2015 -
Author:
Fabrice Farigoule -
Pages:
2
Lonza released its 9m trading statement which does not include any hard numbers (as usual) and only stresses the continued positive momentum in both Speciality Ingredients and Pharma&Biotech. As a reminder, top-line growth in H1 was +5.8% (and +6.5% at CER). The group's outlook remains unchanged (sales growth in reported currency and core EBIT growth above +5% at CER with capex below CHF300m and a reduction in net debt).